| Screening for Cytotoxic Compounds in Poor-prognostic Chronic Lymphocytic Leukemia. | |
| | |
MedLine Citation:
|
PMID: 22843883 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
MATERIALS AND METHODS: We identified substances with equal high cytotoxic activity in vitro in samples from poor-prognostic CLL (11q-/17p-, n=3) as compared to those from favourable-prognostic CLL (13q-, n=3). Cell survival was measured by fluorometric microculture cytotoxicity assay. RESULTS: Out of 2,000 compounds, 65 had a similar effect in both prognostic groups. Fifteen compounds were selected for dose-response experiments in 16 additional CLL samples. Of these compounds, 12 continued to have similar cytotoxicity between prognostic subgroups. Additional experiments demonstrated that in CLL cells with 11q or 17p deletion, 5-azacytidine induced apoptosis in a dose-dependent manner and lipoprotein lipase expression was reduced following orlistat treatment. CONCLUSION: Using primary cultures of cells from high-risk CLL patients for compound screening is a feasible approach and that 5-azacytidine and orlistat exemplify substances that exhibit cytotoxicity in poor-risk CLL. |
| | |
Authors:
|
Maria Norberg; Elin Lindhagen; Meena Kanduri; Linda Rickardson; Christer Sundström; Kostas Stamatopoulos; Richard Rosenquist; Anna Aleskog |
Related Documents
:
|
2483543 - Activity of human placental gamma globulin in blocking immune functions in vitro and in... 15749843 - Recent immune status determines the source of antigens that drive homeostatic t cell ex... 21590763 - Nkg2d performs two functions in invariant nkt cells: direct tcr-independent activation ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Anticancer research Volume: 32 ISSN: 1791-7530 ISO Abbreviation: Anticancer Res. Publication Date: 2012 Aug |
Date Detail:
|
Created Date: 2012-07-30 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8102988 Medline TA: Anticancer Res Country: Greece |
Other Details:
|
Languages: eng Pagination: 3125-36 Citation Subset: IM |
Affiliation:
|
Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, SE-751-85 Uppsala, Sweden. richard.rosenquist@igp.uu.se. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cell-free Serum DNA in Patients with Bladder Cancer: Results of a Prospective Multicenter Study.
Next Document: Improved Gene Transfer into Bladder Cancer Cells Using Adenovirus Vector Containing RGD Motif.